|Bid||13.35 x 1100|
|Ask||18.00 x 4000|
|Day's Range||15.79 - 16.26|
|52 Week Range||13.24 - 21.48|
|Beta (3Y Monthly)||2.50|
|PE Ratio (TTM)||52.34|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.33|
Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF) is pleased to announce that the company will be launching DabTabs™, a revolutionary new product that will alter the way cannabis consumers use cannabis concentrates or oils. The DabTabs™ provide a cleaner, smoother, mess free way to consume full spectrum cannabis concentrates that capture the full benefits of the cannabis plant. The DabTabs™ recently launched in Oregon in late January, with rollouts in Nevada and California in February.
# Halozyme Therapeutics Inc ### NASDAQ/NGS:HALO View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.06 billion over the last one-month into ETFs that hold HALO are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...
- Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation - Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with ...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) net revenues grew ~16% YoY to reach $140.1 million from $120.8 million. In the third quarter, the company’s net revenues amounted to $49.1 million, reflecting ~19% YoY growth. Wall Street analysts estimate that Vanda Pharmaceuticals will generate revenues of $191.7 million in fiscal 2018.
On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SAN DIEGO , Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 37th Annual ...
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") ...
Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.
NEW YORK , Nov. 29, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") (NASDAQ: HALO). Such ...
NEW YORK, Nov. 29, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc..
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Halozyme Therapeutics Inc (NASDAQ:HALO), with a market capitalization of US$2.2b, rarely draw their attention from the investing Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet), ...
-FDA Agrees to Company Request to Change Primary Endpoint to Overall Survival- -Previously Planned Interim Analysis Will Not Be Conducted- -Management to Host Webcast / Conference Call Today at 5 p.m. ...
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...